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ABSTRACT 
 
The burden of premature death and health loss from end-stage renal disease is well-
described.  Less is known regarding the burden of reduced glomerular filtration 
rate-attributable cardiovascular disease.  The prevalence of reduced glomerular 
filtration rate categories 3, 4, and 5 (not on renal replacement therapy) was 
estimated for 188 countries at six time points from 1990 to 2013.  Relative risks of 
cardiovascular outcomes by three strata of reduced glomerular filtration rate were 
calculated by pooled random effects meta-analysis.  Results are presented as deaths 
for outcomes of cardiovascular disease and end-stage renal disease (ESRD), and 
disability-adjusted life years (DALYs) for outcomes of cardiovascular disease and 
CKD categories 3, 4, 5, and ESRD.  In 2013, reduced glomerular filtration rate was 
associated with 4% of deaths worldwide, or 2.2 million deaths (95% uncertainty 
interval: 2.0 to 2.4M). More than half of these attributable deaths were 
cardiovascular deaths (1.2M; 95% UI: 1.1 to 1.4M), while 0.96M (95% UI: 0.81M, 
1.0M) were end-stage renal disease deaths.  Compared with metabolic risk factors, 
reduced glomerular filtration rate DALYs (14th) ranked under high-systolic blood 
pressure (1st), high body-mass index (3rd), high fasting plasma glucose (4th), and 
ranked similarly with high total cholesterol (13th).  By 2013 cardiovascular deaths 
attributed to reduced GFR outnumbered ESRD deaths throughout the world.  
Studies are needed to evaluate the benefit of early chronic kidney disease detection 
and treatment to decrease these deaths.
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INTRODUCTION 
 
Chronic kidney disease (CKD) is prevalent within the general adult population.1-4 
Though general CKD screening is not performed in most countries, surveys 
consistently find that a sizeable proportion of the general adult population has some 
stage of CKD. In the United States, it is estimated that 13.1% of adults have CKD, and 
that CKD prevalence has been increasing over time.1  A survey in Japan found 19.1% 
of the adult population have CKD.2  Determining CKD burden within developing 
countries is more challenging. A recent meta-analysis of CKD prevalence of any 
stage in sub-Saharan Africa estimated a population prevalence of 13.9% among 
adults, though the analysis was limited by availability of few high-quality data 
sources.3 A recent survey in two Indian cities found one in 12 individuals to have 
CKD, and among those with CKD almost 80% were assessed to be at high risk for a 
cardiovascular event.4 These data indicate that CKD is common in diverse parts of 
the world. 
  
The health and social effects of CKD patients who progress to end-stage renal 
disease (ESRD) are well-known.5-7  The burden of health loss and premature 
mortality within the CKD population to cardiovascular (CV) disease is less known.  
Increasing severity of pre-dialysis reduced glomerular filtration rate (GFR) is 
associated with a higher likelihood of CV disease diagnoses, severity, and death.8-11 
Many studies have subsequently demonstrated a consistent association between 
reduced GFR and specific CV diagnoses of congestive heart failure, myocardial 
infarction, stroke, and peripheral vascular disease.8,12-14 This independent 
contribution of reduced GFR to the fatal and nonfatal CV disease burden has not yet 
been quantified at a population-level. 
 
Understanding the true societal impact of CKD requires evaluating the independent 
burdens of ESRD and reduced GFR-associated CV disease. Such data would guide 
national priorities regarding the benefit of early CKD detection.15  Early CKD 
detection and management could defray costs related to eventual ESRD 
development and higher likelihood of CV disease development.16  Thus, we aim to 
determine the burden of CV disease due to reduced GFR among 188 countries, 
compare this to the ESRD burden, and evaluate how this combined burden ranks 
among leading causes of health loss and premature death.   
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RESULTS 
Global reduced-GFR mortality and DALYs in 2013 
In 2013, 2.2 million deaths were associated with reduced GFR (Table 1, Figure 1).17 
Nearly 52 million DALYs were associated with reduced GFR (Table 1, Figure 2).  
These attributable deaths and DALYs account for 3.9% of total global deaths and 
2.1% of total global DALYs in 2013, respectively (Table 1).   
 
Changes in reduced GFR death and DALY rates since 1990 
At the global level, among all ages, GFR-attributable median death and DALY counts 
have increased by 65.6% and 52.0%, respectively, whereas age-standardized rates 
of deaths and DALYs associated with reduced GFR have decreased by 10% and 
8.1%, respectively (Tables 1-2, Figures 3-4). Compared with other metabolic risk 
factors, since 1990, among all ages, DALYs attributed to high fasting glucose (69.6%; 
UI: 60.9, 78.7); high total cholesterol (26.9%; UI: 19.8; 36.3); and high blood 
pressure (49.1%; UI: 43.2, 55.2) have all increased. Age-standardized DALY rates for 
the risk factors high blood pressure (-16.5; UI: -20.0, -12.5) and high total 
cholesterol (-27.5; UI: -31.5, -22.1) have decreased, whereas DALY rates associated 
with high fasting glucose remained relatively constant (0.2%; UI: -4.8, 5.6).  
 
Geographic patterns for reduced GFR mortality in 2013 
Among super-regions, reduced GFR ranked highest in Latin America/Caribbean 
(5th), with 7.0% of total deaths attributed and outranking metabolic risk factor high 
total cholesterol (7th).  Within the High-income super-region, reduced GFR ranked 
8th and was outranked by all metabolic risk factors except for low bone mineral 
density (17th).  Reduced GFR ranked lowest in Sub-Saharan Africa (16th), though still 
out-ranked “high total cholesterol” (25th) for deaths (Figure 5). 
 
Cardiovascular disease attributed to reduced GFR 
Throughout the world in 2013, there were 1.2 million CV deaths attributed to 
reduced GFR, with an age-standardized rate of 20.8 deaths per 100,000 (Table 2). 
Since 1990, reduced GFR associated-CV deaths have increased by 33.8% (UI: 24.6, 
43.8), while the age-standardized GFR-attributable rate has decreased by 28.6% 
(Table 2). The 2013 age-standardized CV mortality rate within the developing world 
(21.5 per 100,000) was slightly higher than in the developed world (19.2 per 
100,000) (Table 2). Notably, the age-standardized CV mortality rate in the 
developing world has decreased slightly since 1990 (9.5% decline), whereas the 
developed world has demonstrated a 44% decline in age-standardized CV mortality 
(Table 2). 
 
Reduced GFR was responsible for 18.7 million CV DALYs in 2013 among all ages, 
and an age-standardized rate of 304.2 DALYS per 100,000 (Table 3, Figure 6). The 
developing world region had a higher rate, as well as smaller decrease in rate since 
1990 when compared to the developed world (Table 3).   
Among super-regions, the highest age-standardized GFR-attributed CV mortality 
rates were estimated for Central Europe, Eastern Europe, Central Asia, and sub-
Saharan Africa (Table 2). Since 1990, GFR-attributed cardiovascular mortality rates 
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in sub-Saharan Africa and South Asia tended to increase, as opposed to all other 
super-regions. The High-income world region demonstrated the greatest decrease 
in mortality rate since 1990 (Table 2). 
 
ESRD deaths and CKD DALYs 
Globally there were 956,246 (UI: 812,896, 1,034,491) deaths due to ESRD in 2013, 
with an age-standardized rate of 15.8 per 100,000 (Table 2). Since 1990, both the 
number of deaths (134.6%; 95% UI: 115.7%, 150.2%) and age-standardized 
mortality rate (36.9%) have increased (Table 2). The age-standardized mortality 
rate in the developing world was almost twice that of the developed, and has 
increased by 44.7% since 1990, compared to the 9.8% increase within the 
developed world (Table 2). 
 
The super-region with highest ESRD mortality rate in 2013 was Latin 
America/Caribbean, with an ESRD mortality rate of 32/100,000, which is almost 
double the global rate (Tables 2, Figure 7). South Asia demonstrated the greatest 
increase in CKD deaths (82.9%) since 1990, though all developing super-regions 
demonstrated an increase in ESRD mortality (Table 2).  
 
At the global level, age-standardized ESRD DALY rates have increased by 12.3%, but 
this increase largely occurred within the developing world (Table 3). 2013 ESRD 
DALY rates were highest in the Latin America and Caribbean region (829/100,000), 
and lowest for Central Europe, Eastern Europe, Central Asia (398/100,000) and 
Southeast Asia, East Asia, and Oceania (393/100,000) (Table 3). Age-standardized 
rates have decreased in three world regions since 1990 (Central Europe, Eastern 
Europe, and Central Asia (-6.7%), High-income (-0.7%), and North Africa and Middle 
East (-3.1%).  The largest increases in age-standardized CKD DALY rates occurred in 
Latin America and Caribbean (39.1%) and South Asia (39.6%), driving the notable 
increase in the CKD DALY rate within the developing world in comparison to the 
developed world. 
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DISCUSSION 
The Global Burden of Diseases, Injuries, and Risk Factors Study 2013 ranks reduced 
GFR as the 12th leading risk factor for death at the global level, and the 14th risk 
factor for DALYs among 79 risk factors in 2013.18 Within world regions such as 
High-income and Latin America and Caribbean, the mortality ranking was as high as 
eighth and fifth, respectively. This analysis provides granular detail regarding the 
contribution of CV disease caused by reduced GFR to these rankings. In 2013, more 
than 2 million deaths and 52 million DALYs were associated with reduced GFR. 
More than half of attributable deaths were estimated to have occurred secondary to 
CV disease.  
 
The Global Burden of Disease Study indicates that in 1990, the developed world 
demonstrated notably higher rates of total CV disease than developing world 
regions.19,20  Over time, the burden of total fatal CV disease has markedly declined in 
the developed world, whereas it has increased within developing regions.20 These 
shifting patterns of total CV disease activity in the developed and developing worlds 
are driving the overall pattern that we report of GFR-attributable CV DALY and 
death activity. There are likely three factors contributing to the increase in total CV 
disease mortality within the developing world. First, improved success in treating 
leading causes of premature mortality within resource-limited nations, mainly 
related to infectious diseases and maternal-perinatal mortality, has allowed 
individuals to reach more advanced age and thus develop conditions related to 
aging.21 Second, the shift in diet towards greater intake of animal fat and high-
caloric food has been documented within the developing world for at least the past 
decade, facilitating CV disease development. Third, limited implementation of 
cardiovascular risk factor detection, treatment, and disease management within the 
developing world in the setting of a growing burden led to sustained mortality 
rates.20-22   The differences between age-standardized and all age rates merit further 
research. 
 
Our results which show the attributable CV burden within the developed world may 
illustrate the success within regions such as North America and Western Europe in 
addressing risk factors for incident CV disease over the past decades.23  Importantly, 
when comparing the reduced GFR risk factor to other CV risk factors such as high 
blood glucose, high blood pressure, elevated total cholesterol, and smoking, reduced 
GFR and elevated fasting glucose had the lowest decrease in DALY rates within the 
past two decades.17 This finding suggests that building on the success of CV risk 
factor detection and treatment will require paying equal attention in the coming 
years to more novel CV risk factors, such as reduced GFR.  
 
The potential public health benefits of CKD screening have been evaluated in the 
past.15,25,26  Cost-effectiveness CKD screening studies that fully incorporated fatal 
and non-fatal CV outcomes as well as incident ESRD have concluded CKD screening 
within the general population to be cost-effective, in opposition to results of studies 
that only incorporated ESRD outcomes and fatal CV disease.16,24,25 Our results are 
the first to quantify and compare ESRD and reduced GFR attributable CV outcomes 
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across developed and developing nations, and illustrate that ESRD represents less 
than half of health events attributable to reduced GFR, even within the developing 
world.  This reiterates the importance of CV fatal and nonfatal disease incorporation 
into evaluations of the health and economic benefits of population CKD screening.  
Within low- and middle-income nations, it is possible that CKD screening is of even 
higher importance in forestalling ESRD development, since renal replacement 
therapy is limited in more than half of the world’s countries.26 
 
There is need for evidence demonstrating that slowing CKD progression lowers 
cardiovascular disease incidence and mortality.  Despite this there are strong 
arguments for population-level CKD screening.  CKD screening using even urinalysis 
could potentially improve screening for hypertension and diabetes, the treatment of 
which would forestall CKD progression.27 28  Within developed nations, there are 
screening recommendations for diabetes and hypertension, but if CKD is advanced 
at the time of detection, management of diabetes and hypertension is more 
challenging.29   
 
Within developing countries, access to care is a barrier to chronic disease detection 
and treatment.19,30  Literature suggests that the prevalence of undiagnosed 
hypertension and diabetes is higher in developing than developed nations.30  Yet 
there are examples of cost-effective efforts to detect and treat chronic diseases even 
within resource-limited settings.  The non-profit organization MoPoTsyo employs a 
community health worker approach to screen rural Cambodian adults for diabetes, 
hypertension, obesity, and CKD and initiates treatment for these conditions, paired 
with diet and lifestyle modification and strict follow-up.31  Results from this 
organization indicate very favorable control of diabetes mellitus, hypertension, and 
CKD progression.32  Similar results have been published for chronic disease 
outreach programs in the Philippines and DR Congo.33  Such novel screening and 
management interventions illustrate the importance and feasibility of chronic 
disease detection and management to delay progression even in remote settings.   
 
CKD DALYs and ESRD deaths have been increasing globally because of increasing 
ESRD burden in developing nations.34 This pattern is also likely multi-factorial. 
Possible additional contributors to those discussed above include the increasing 
global burden of obesity and diabetes mellitus, known leading causes of CKD.35,36 Of 
concern is the limited infrastructure within many developing nations to provide 
maintenance renal replacement therapy or renal transplantation for individuals 
with advanced CKD, considering that such countries healthcare systems are already 
burdened with management of infectious diseases and malnutrition.26,37   
 
Within the developed region, though CKD DALY rates have decreased slightly since 
1990, mortality rates have not, which could be explained in part by increasing age at 
death. This is in notable contrast to the almost 45% reduction over that time period 
in CV disease deaths associated with reduced GFR within the developed world. 
Success in addressing this CKD burden will likely involve continued efforts at early 
diagnosis and treatment of hypertension, diabetes mellitus, and also early-stage 
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CKD. These measures will also be necessary within developing nations, coupled with 
infrastructure development for treatment of ESRD.38,39 
 
Within certain regions, unique contributors to ESRD development require focused 
attention by that nation’s healthcare infrastructure.  This concerns not only usually 
considered diabetes mellitus, hypertension, HIV and other well-known factors 
leading to kidney damage — but also the chronic kidney disease of unknown etiology 
(CKDu). The later studied recently mainly in specific Latin American and Southeast 
Asian countries40-44, with several hypothesized causes including environmental 
exposures, toxins, and climate change, but to date there is no clear etiological factor 
was revealed.45  CKDu often targets young men to a higher degree than CKD caused 
by known factors,40-44 and is now considered endemic in countries such as Sri 
Lanka, India, El Salvador and Nicaragua, and is the leading cause of hospital deaths 
in El Salvador.45,46 The challenges surrounding the CKDu epidemic exemplify how 
methods for detecting and addressing CKD burden may have to extend beyond 
screening for traditional CKD risk factors within classically defined high-risk 
portions of the population in order to prevent ESRD deaths and CKD DALYs. 
 
Making global estimates inherently requires assumptions and has limitations.  First, 
the CKD prevalence data was only available for 44 countries and among the more 
than 1000 surveys, methods were often not optimal and within most countries, not 
all time points were included.  The Bayesian methods provide the best estimates 
possible but are limited by the quality of the available data.  Furthermore, 
inconsistency of data collection of time and world region could influence trends and 
geographic variation. An area for improvement of this analysis involve 
incorporating albuminuria into the exposure definition for PAF calculation. There is 
strong evidence in the literature demonstrating the independent association 
between albuminuria and CV events, in isolation of and in addition to reduced 
GFR.47 Thus the estimates that we present might possibly underestimate the true 
burden of cardiovascular events associated with CKD. These limitations serve as 
steps for improvement of future estimations.  
 
A significant strength of this study involves the relative risk determination for 
incident CV events by stage of kidney dysfunction in a global consortium.  Further 
strengths involve our ability to estimate fatal and non-fatal burden for specific CV 
diseases as well as ESRD throughout the world and across time.   
 
The death rate from ESRD is increasing throughout the world and is a leading cause 
of death in world regions such as Central Latin America. Efforts to forestall such 
rates will involve detecting CKD earlier. Affordable means of detecting early-stage 
CKD are available, as well as affordable means of treating early stage CKD to delay 
progression.48  In order to evaluate whether such screening methods should be 
recommended for the general population, further cost-effectiveness analyses will 
need to be conducted that incorporate the 1.2 million CV disease deaths throughout 
the world attributable to reduced GFR. It will be difficult to alter death rates within 
the CKD population without such studies and screening efforts.   
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CONCISE METHODS 
Study overview 
This analysis follows the risk assessment framework used in the Global Burden of 
Disease (GBD) Study 2013 for 79 individual and combined risk factors, where 
prevalence of the exposure is determined, a theoretical minimum risk is defined, 
and the relative risk of a causally related health outcome is quantified.18,49  
 
Population-attributable fractions (PAFs) 
We calculated the CV fatal and nonfatal burden attributable to the categorical 
exposure of reduced GFR categories using the following equation: 
 
 
 
Equation 1. PAF based on categorical exposure 
 
where RRi is the relative risk for exposure level i, Pi is the proportion of the 
population in that exposure category, and n is the number of exposure categories.50  
 
Exposure 
An overview of the modeling method used for determining country-level prevalence 
of GFR categories <15ml/min/1.73m2 (not on dialysis), 15-30 ml/min/1.73m2, 30-
60 ml/min/1.73m2 is provided in the accompanying appendix (A.2.). We used these 
country prevalence estimates of reduced GFR categories as our exposure categories. 
 
Relative risk determination 
Relative risks of cardiovascular outcomes of ischemic heart disease and stroke per 
GFR exposure category were derived from cohort data included in the Chronic 
Kidney Disease Prognosis Consortium (14 cohorts, n = 135,484) with estimated 
kidney function based on serum creatinine and prospective assessment of fatal and 
nonfatal cardiovascular events (Supplemental Table 3).51  The relative risk for 
peripheral vascular disease by stage of reduced renal function was determined from 
the Atherosclerotic Risk in the Communities (ARIC) cohort.  We attributed 100% of 
ESRD incidence and mortality to reduced GFR (details provided in Appendix A.3. 
“Relative Risk determination”). 
 
Outcomes 
CV outcomes of IHD, stroke, and PVD, ESRD deaths and CKD DALYs at the 
country/age/sex/year level were obtained from the Global Burden of Disease 2013 
Study (Appendix A.4.)    
 
World regions 
The countries of which regions and super-regions are comprised are listed in 
Supplemental Table 1.   
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FIGURE LEGENDS 
 
Figure 1.  a.  Age-standardized deaths per 100,000 in 2013 attributed to reduced 
GFR 
b.  Age-standardized DALYs per 100,000 in 2013 attributed to reduced GFR 
 
Figure 2.  a.  Age-standardized mortality rate attributed to reduced GFR at the 
global, developed, and developing levels at 6 time-points between 1990 and 2013 
                   b.  Age-standardized DALY rate attributable to reduced GFR at the global, 
developed, and developing levels at 6 time-points between 1990 and 2013 
 
Figure 3.  Risk factor ranking for deaths in 2013 per 100,000 among seven super-
regions 
 
Figure 4.  Cardiovascular DALYs per 100,000 attributable to reduced GFR in 2013 
 
Figure 5.  Chronic Kidney Disease (CKD categories 3,4,5, and maintenance dialysis) 
DALYS per 100,000 attributable to reduced GFR in 2013 
 
 
 
 
